Position in PTGX
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$122,580
+$17,180 QoQ
Shares Held
1,000
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#273
of 343 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Canton Hathaway, LLC holds $783,315 across 6 Biotechnology names. PTGX ranks #3 (15.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BHVN |
Biohaven Ltd.
|
22,600 | $336,288 | |
| 2 | INCY |
Incyte Corp
|
1,500 | $170,040 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
This page
|
1,000 | $122,580 | |
| 4 | CHRS |
Coherus Oncology, Inc.
|
58,230 | $81,522 | |
| 5 | MRNA |
Moderna, Inc.
|
601 | $42,088 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
62 | $30,797 |
All Filings in PTGX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $122,580 | 1,000 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $105,400 | 1,000 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $87,340 | 1,000 | Shares | Sole | 2026-01-21 | |
| No filing history on record for this holder in this stock. | ||||||